Premium
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Author(s) -
Mollenhauer Brit,
Dakna Mohammed,
Kruse Niels,
Galasko Douglas,
Foroud Tatiana,
Zetterberg Henrik,
Schade Sebastian,
Gera Roland G.,
Wang Wenting,
Gao Feng,
Frasier Mark,
Chahine Lana M.,
Coffey Christopher S.,
Singleton Andrew B.,
Simuni Tanya,
Weintraub Daniel,
Seibyl John,
Toga Arthur W.,
Tanner Caroline M.,
Kieburtz Karl,
Marek Kenneth,
Siderowf Andrew,
Cedarbaum Jesse M.,
Hutten Samantha J.,
Trenkwalder Claudia,
Graham Danielle
Publication year - 2020
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28206
Subject(s) - biomarker , parkinson's disease , neurofilament , cohort , medicine , neuroprotection , disease , oncology , degenerative disease , pathology , biology , immunohistochemistry , biochemistry
Abstract Background The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker. Methods We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson's disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson's disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers. Results In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson's disease patients versus controls ( P < 0.01). Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores showed a negative association. Conclusions Neurofilament light chain in serum samples is increased in Parkinson's disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson's disease severity. Although the specificity of neurofilament light chain for Parkinson's disease is low, it is the first blood‐based biomarker candidate that could support disease stratification of Parkinson's disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.